MCM2

Across TCGA pan-cancer cohorts, MCM2 RNA is linked to patient survival in 30 of 34 cancer types, making it the most broadly survival-associated MCM2 data layer compared with 8 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher MCM2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MCM2 expression acts as an unfavorable survival marker, although some lineages such as UVM and SCLC show a favorable association.

MESO, ACC, and UVM are the cancer types where MCM2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.259	0.515	<.001	132	view →
ACC	DFS	Median	All	0.217	0.676	<.001	102	view →
UVM	OS	Median	All	0.809	0.402	<.001	100	view →
LIHC	DFS	Median	All	0.445	0.632	<.001	85	view →
LGG	OS	Median	All	0.728	0.892	<.001	53	view →
KICH	DFS	Median	All	0.681	1.000	.006	52	view →
PAAD	OS	Tertile	All	0.268	0.530	<.001	48	view →
SCLC	OS	Tertile	II,III,IV	0.738	0.217	<.001	37	view →
UCS	OS	Quartile	II,III,IV	0.708	0.317	.009	36	view →
KIRP	DFS	Median	All	0.859	0.955	<.001	29	view →
SARC	DFS	Quartile	All	0.501	0.684	.002	24	view →
CHOL	DFS	Median	II,III,IV	0.121	0.626	.002	23	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 30 lineages.

MCM2–MESO (OS)

Open the MESO breakdown →